Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 8:12:640137.
doi: 10.3389/fneur.2021.640137. eCollection 2021.

Screen Fast, Screen Faster: A Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast Screen in Parkinson's Disease With Mild Cognitive Impairment

Affiliations

Screen Fast, Screen Faster: A Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast Screen in Parkinson's Disease With Mild Cognitive Impairment

Saskia Elben et al. Front Neurol. .

Abstract

Objective: Depressive symptoms have a high prevalence in patients with Parkinson's disease (PD) and are associated with cognitive dysfunction. Especially in PD with mild cognitive impairment (MCI), a time-efficient and valid instrument for the assessment of depression primarily focusing on psychological symptoms and disregarding confounding somatic symptoms is needed. We performed an examination of the psychometric properties of the Beck Depression Inventory II (BDI-II) and the Beck Depression Inventory Fast Screen (BDI-FS). Methods: The sample consisted of 64 patients [22 females and 42 males, mean age: 67.27 years (SD = 7.32)]. Depressive symptoms were measured in a cohort of PD patients with MCI. For the BDI-II and BDI-FS the psychometric concepts of internal consistency, convergent validity and diagnostic agreement were assessed. Results: Patients gave higher ratings on test items addressing somatic symptoms than those addressing non-somatic ones. The correlation between the absolute total scores of the BDI-II and the BDI-FS was significant (r = 0.91, p < 0.001), which indicated convergent validity. The Cronbach's alpha values indicated adequate internal consistencies for both measures (BDI-II: 0.84; BDI-FS: 0.78). There was a higher than chance level agreement of diagnoses of the two questionnaires, measured by Cohen's kappa (0.58, p < 0.001). The agreements between previous diagnosis of depression and the diagnoses of the BDI-II/BDI-FS were also significantly higher than chance level (BDI-II: 0.34, p = 0.007, BDI-FS: 0.39, p = 0.002). Additional AUC analysis across different cutoffs showed that performance of BDI-FS was better than BDI-II, supporting the observation of an equivalent or better performance of BDI-FS than BDI-II. Importantly, AUC analysis confirmed that a cutoff = 4 for BDI-FS was suitable in the considered sample of patients with PD-MCI. Discussion: In a cohort of PD-MCI, the BDI-FS demonstrates adequate psychometric properties in comparison to the BDI-II and can be used as a screening measure for assessing depression in cognitively impaired PD patients, focusing solely on psychological symptoms. Still, further research is needed to validate this instrument.

Keywords: BDI-FS; BDI-II; Parkinson's disease; depression; mild cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

AK-F has received a grant from the German Parkinson Society and honoraria from ProLog Wissen GmbH, Cologne, Germany, and pro audito Switzerland, Zürich, Switzerland. NS has received grants from the German Federal Ministry of Education and Research. KW has received grants for the German Research Foundation, the German Federal Ministry of Education and Research, and received speaker honoraria from BIAL, BAYER, Medtronic, Boston Scientific, Novartis, Desitin, and the German Society of Neurology. IL-S has received grants from the Parkinson Fonds Deutschland gGmbH, Janssen Pharmaceutical Companies of Johnson & Johnson, European Commission, H2020-TWINN-2015, and the Michael J. Fox Foundation. EK has received grants from the German Ministry of Education and Research, Parkinson Fonds Deutschland gGmbH, and the German Parkinson Society and honoraria from Oticon GmbH, Hamburg, Germany; Lilly Pharma GmbH, Bad Homburg, Germany; Bernafon AG, Bern, Switzerland; and Desitin GmbH, Hamburg, Germany. LW has received honoraria from Meda, Boehringer, Cephalon Pharma, TEVA, Desitin, AbbVie St. Jude Medical / Abbott, and Medtronic and grants from HHU Düsseldorf, DFG Forschergruppe (FOR 1328), ERANET Neuron/BMBF (TYMON 01EW141), German Parkinson's Disease Association (dPV), Parkinson Fonds Germany, and Hilde Ulrichs Stiftung für Parkinsonforschung. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
“Area under ROC” (AUC) analysis. (A) AUC of ROC corresponding to BDI-FS across different cutoffs: 0–9. It is noticeable that highest performance is achieved at cutoff = 4; (B) AUC of ROC corresponding to BDI-FS across different cutoffs: 0–20. It is noticeable that highest performance is achieved at cutoff = 15 and 16; (C) ROC of BDI-FS (cutoff = 4) corresponding to logistic regression model: depression-state = 2.4927*BDI-FS −1.6818, p < 0.001 (coefficient and intercept) and ROC of BDI-II (cutoff = 15 and 16) corresponding to logistic regression model: depression-state = 2.3289*BDI-II −1.4816, p = 0.0026 (coefficient), p < 0.001 (intercept). For the considered sample of PD-MCI patients, better performance of BDI-FS than BDI-II was revealed.
Figure 2
Figure 2
Mean item score values for all items of the BDI-II. The x-axis represents the 21 items of the BDI-II and the 7 BDI-FS items Sadness, Pessimism, Past Failure, Loss of Pleasure, Self-Dislike, Self-Criticalness, and Suicidal Ideation (dark columns). The y-axis depicts the mean scores (and standard deviation) on the individual items with scores ranging from 0 to 3. The items in the second half of the questionnaire address somatic symptoms and mostly received higher scores in our sample than the non-somatic items of the first half.

References

    1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. (1999) 56:33–9. - PubMed
    1. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease—epidemiology, mechanisms and management. Nat Rev Neurol. (2012) 8:35–47. 10.1038/nrneurol.2011.189 - DOI - PubMed
    1. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology. (1981) 31:645–5. - PubMed
    1. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord. (2006) 21:1343–9. 10.1002/mds.20974 - DOI - PubMed
    1. Global Parkinson's Disease Survey (GPDS) Steering Committee . Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. (2002) 17:60–7. 10.1002/mds.10010 - DOI - PubMed

LinkOut - more resources